These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 26850086)
1. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging. Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086 [TBL] [Abstract][Full Text] [Related]
2. Identification of a Glypican-3-Binding Peptide for In Vivo Non-Invasive Human Hepatocellular Carcinoma Detection. Qin Z; Wang J; Wang Y; Wang G; Wang X; Zhou Z; Liu G; Gao S; Zhu L Macromol Biosci; 2017 Apr; 17(4):. PubMed ID: 27862961 [TBL] [Abstract][Full Text] [Related]
3. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748 [TBL] [Abstract][Full Text] [Related]
4. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341 [TBL] [Abstract][Full Text] [Related]
5. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody. Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949 [TBL] [Abstract][Full Text] [Related]
6. The development of a Glypican-3-specific binding peptide using Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851 [TBL] [Abstract][Full Text] [Related]
7. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression. Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870 [TBL] [Abstract][Full Text] [Related]
8. An innovative peptide with high affinity to GPC3 for hepatocellular carcinoma diagnosis. Zhang Q; Han Z; Tao J; Zhao M; Zhang W; Li P; Tang L; Gu Y Biomater Sci; 2018 Dec; 7(1):159-167. PubMed ID: 30417190 [TBL] [Abstract][Full Text] [Related]
9. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice. Dargel C; Bassani-Sternberg M; Hasreiter J; Zani F; Bockmann JH; Thiele F; Bohne F; Wisskirchen K; Wilde S; Sprinzl MF; Schendel DJ; Krackhardt AM; Uckert W; Wohlleber D; Schiemann M; Stemmer K; Heikenwälder M; Busch DH; Richter G; Mann M; Protzer U Gastroenterology; 2015 Oct; 149(4):1042-52. PubMed ID: 26052074 [TBL] [Abstract][Full Text] [Related]
10. Berman RM; Kelada OJ; Gutsche NT; Natarajan R; Swenson RE; Fu Y; Hong J; Ho M; Choyke PL; Escorcia FE Cancer Biother Radiopharm; 2019 Oct; 34(8):498-503. PubMed ID: 31424293 [No Abstract] [Full Text] [Related]
11. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells]. Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080 [TBL] [Abstract][Full Text] [Related]
12. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434 [TBL] [Abstract][Full Text] [Related]
13. Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma. Luan F; Liu P; Ma H; Yue X; Liu J; Gao L; Liang X; Ma C Int J Biochem Cell Biol; 2014 Oct; 55():129-35. PubMed ID: 25195714 [TBL] [Abstract][Full Text] [Related]
14. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Zhou F; Shang W; Yu X; Tian J Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802 [TBL] [Abstract][Full Text] [Related]
16. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. Filmus J; Capurro M FEBS J; 2013 May; 280(10):2471-6. PubMed ID: 23305321 [TBL] [Abstract][Full Text] [Related]
17. The significance of glypican-3 expression profiling in the tumor cellular origin theoretical system for hepatocellular carcinoma progression. Xue R; Feng J; Meng Q; Lv F; Zhu Y; Yu H; Zhang S; Song C; Sun L; Yue Z; Feng S; Che R; Xiang Q; Jing X J Gastroenterol Hepatol; 2017 Aug; 32(8):1503-1511. PubMed ID: 28087980 [TBL] [Abstract][Full Text] [Related]
18. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Wu Y; Liu H; Weng H; Zhang X; Li P; Fan CL; Li B; Dong PL; Li L; Dooley S; Ding HG Int J Oncol; 2015 Mar; 46(3):1275-85. PubMed ID: 25572615 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840 [TBL] [Abstract][Full Text] [Related]
20. Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma. Montalbano M; Rastellini C; McGuire JT; Prajapati J; Shirafkan A; Vento R; Cicalese L Cell Oncol (Dordr); 2018 Apr; 41(2):169-184. PubMed ID: 29204978 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]